Cradle

Name: Cradle
Brand: Cradle

AI Native

Engineer better proteins, faster.

Est 2021|Raised $102.5M|2 Ref Customers

LinkedIn 30K|Web traffic 14K|FTEs 124|HQ Amsterdam, North Holland, NL

01Competitive Landscape

Narrative analysis: differentiators and tradeoffs

- Cradle vs vertically integrated biotech partners: Cradle's subscription model emphasizes software licensing and vendor-stated IP retention, which may suit organizations that prefer to retain program control rather than enter revenue-sharing partnerships. - Cradle vs in-house ML capabilities: Organizations with mature internal ML and lab automation may replicate aspects of Cradle’s functionality. Buyers should benchmark vendor performance against internal baselines. - Cradle vs ELN/LIMS vendors: Platforms such as Benchling serve as experiment management systems of record and are typically complementary to protein-design tools; integration capability and maturity are important selection criteria.

	Cradle (cradle.bio)	Profluent (profluent.bio)	Generate:Biomedicines
Starting Price	Not publicly listed (vendor states annual license per active project; contact sales)	Not publicly listed on website	Not applicable (vertically integrated biotech; not a standard software subscription)
Best For	Teams seeking a subscription software platform to run iterative protein optimization workflows using in-house wet-lab data, with vendor-stated IP retention	Organizations seeking AI-authored protein capabilities via partnerships or platform-based access	Organizations pursuing therapeutic programs with a vertically integrated AI biotech partner
Key Strength	Subscription software model with project-based licensing; UI and API access; vendor emphasis on privacy/IP control	Platform- and partnership-focused approach for protein design	Vertical integration focused on therapeutic development with internal datasets and wet lab capacity
Key Weakness	Limited public third-party reviews and limited public compliance detail; vendor-published performance claims need independent validation	Product and access models can be partnership-driven and are not directly comparable to a software SKU	Not a drop-in software product; partnership model may provide less customer control for organizations wanting in-house capabilities

01Competitive Landscape

Narrative analysis: differentiators and tradeoffs

Cradle vs vertically integrated biotech partners: Cradle's subscription model emphasizes software licensing and vendor-stated IP retention, which may suit organizations that prefer to retain program control rather than enter revenue-sharing partnerships.
Cradle vs in-house ML capabilities: Organizations with mature internal ML and lab automation may replicate aspects of Cradle’s functionality. Buyers should benchmark vendor performance against internal baselines.
Cradle vs ELN/LIMS vendors: Platforms such as Benchling serve as experiment management systems of record and are typically complementary to protein-design tools; integration capability and maturity are important selection criteria.

	Cradle (cradle.bio)	Profluent (profluent.bio)	Generate:Biomedicines
Starting Price	Not publicly listed (vendor states annual license per active project; contact sales)	Not publicly listed on website	Not applicable (vertically integrated biotech; not a standard software subscription)
Best For	Teams seeking a subscription software platform to run iterative protein optimization workflows using in-house wet-lab data, with vendor-stated IP retention	Organizations seeking AI-authored protein capabilities via partnerships or platform-based access	Organizations pursuing therapeutic programs with a vertically integrated AI biotech partner
Key Strength	Subscription software model with project-based licensing; UI and API access; vendor emphasis on privacy/IP control	Platform- and partnership-focused approach for protein design	Vertical integration focused on therapeutic development with internal datasets and wet lab capacity
Key Weakness	Limited public third-party reviews and limited public compliance detail; vendor-published performance claims need independent validation	Product and access models can be partnership-driven and are not directly comparable to a software SKU	Not a drop-in software product; partnership model may provide less customer control for organizations wanting in-house capabilities

Cradle

01Competitive Landscape

Narrative analysis: differentiators and tradeoffs

02Market Map

01Competitive Landscape

Narrative analysis: differentiators and tradeoffs

02Market Map